急性冠脉综合征早期辅助应用麝香保心丸治疗的作用及安全性临床研究  

The Clinical Study of Shexiang Baoxin Wan as an Ancillary Treatment in Acute Coronary Syndrome

作　　者：曾群英[1] 王礼春[1] 高修仁[1] 廖学新[1] 郑东诞[1] 许庆[1] 王强[1] 陶军[1] 陈国伟[1] 

机构地区：[1]广州中山医科大学附属第一医院心内科

出　　处：《中西医结合心脑血管病杂志》2003年第4期221-223,共3页Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease

摘　　要：目的 :探讨急性冠脉综合征(ACS)早期辅助应用中药麝香保心丸(SXBXW )治疗有效性、安全性和预防心脑血管事件的益处。方法 :将 15 3例ACS病人随机单盲分为两组 :SXBXW组 (治疗组 ) 77例 ,SXBXW每次 2丸 (每丸 2 2 .5mg) ,1日 3次 ;安慰剂组 (对照组 ) 76例 ,安慰剂每次 2粒 ,1日 3次。两组均按ACS常规治疗 ,且随访 1年 ,观察两组抗心绞痛疗效、心功能改变、心脑血管事件发生情况及不良反应发生情况。结果 :治疗组显著改善心绞痛 (AP)症状 (总有效率 88.3 % ) ;改善AP的缺血心电图(总有效率 5 7.4% ) ,二者均优于对照组 (P均 <0 .0 5 ) ;治疗组随访 1年中复发性AP、非致死性心肌梗死 (MI)、心力衰竭 (HF)、需做经皮腔内冠脉成形术 /冠脉旁路移植术 (PTCA/CABG)、需再住院治疗的病例均较对照组明显降低 (P <0 .0 5 ) ;SXBXW治疗 3个月明显改善左心室射血分数(LVEF)、左心室短轴缩短率 (FS)、二尖瓣快速充盈期和心房收缩期血流速度比 (E/A) ,且明显优于对照组 (P均<0 .0 5 )。治疗组降低C -反应蛋白(CRP)、纤维蛋白原 (FIB)和D -二聚体作用均明显优于对照组 (P均 <0 .0 5 ) ,且SXBXW辅助治疗ACS不良反应轻微。结论 :ACS早期辅助应用SXBXW有效安全 ,可预防心脑血管事件发生 ,作为辅助药物之一值得推广应用。Objective:To observe the clinical effect and safety of traditionary Chinese medicine Shexiang Baoxinwan (SXBXW) in acute coronary syndrome (ACS) as an ancillary treatment.Methods:153 cases of ACS were assigned two groups randomly and simple blindly. In addition to standard treatment of ACS, one group ( treatment group,n=77) was added SXBXW 2 pills three times per day; the other was given placebo as control. All cases were followed up 1 year, and the effect of treatment, the changing in cardiac function and the occurrence of cardiocerebral events were observed.Results:The severity and reoccurrence of angina pectoris were decreased significantly in treatment group (total effective rate 88.3%,P<0.05). In treatment group, the ischemic electrocardiograph also was significantly improved (total effective rate 57.4%, P<0.05). The events such as recured angina pectoris, nonfatal acute myocardial infarction, heart failure , the need for percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafty (CABG) and the rate of re-hospitalizing were significantly lower in treatment group (P<0.05). Left ventricular ejective fraction (LVEF), fractional shortening of minor-semi axis (FS), the ratio of peak flow velocity between early diastole and atrial contraction (E/A) were great significantly 3 months later in the treatment group than the control .(all P<0.05). CRP, FIB and D-dimer were significantly decreased in the treatment group too. And The adverse reactions were similar and mild in the two groups.Conclusion:SXBXW is safe and more effective assistant treatment in acute coronary syndrome.

关 键 词：急性冠脉综合征 早期辅助应用 麝香保心丸 治疗 有效性 中药 

分 类 号：R541.4[医药卫生—心血管疾病]